G enotyping of CYP2D6 has been mentioned as one of the first pharmacogenetic tests to be implemented in daily clinical practice to improve the outcomes of pharmacotherapy.P The suggested high clinical relevance of CYP2D6 genotyping originates, among other reasons, from a relatively high prevalence of variant alleles in the white population, as well as the expected high prevalence of use of drugs metabolized by CYP2D6. Approximately 5-10% of white people can be classified as poor metabolizers (PMs) by lacking CYP2D6 activity and 1-10 % as ultrarapid metabolizers (UMs) by gene duplication resulting in high enzyme activity.' Furthermore, several reports have suggested that CYP2D6 is involved in the metabolism of approximately 20-30% of all available drugs." Therefore, in white populations, millions of people are potentially at risk for compromised metabolism and the associated clinical complications.
tance of CYP2D6 might be overestimated because manyrecently introduced antidepressants (eg,citalopram, sertraline) and antipsychotics (eg, olanzapine, quetiapine) are not primarily metabolized by CYP2D6. 8 If the prevalence of drugs metabolized by CYP2D6 is not as high as expected, this would reduce the likelihood of genotyping beingcost-effective in daily clinical practice. The objective of this study wasto investigate the prevalence of patients in different patient populations usingdrugsmetabolized by CYP2D6.
Methods

DESIGN AND POPULATION
A cross-sectional design was used to assess the prevalence of patients in different populations using CYP2D6 substrates. The study was conducted within the Departmentof Clinical Pharmacy of the Wilhelmina Hospital Assen, located in the northern part of the Netherlands. This pharmacy is responsible for the pharmaceutical care of approximately 3000 patients admittedto 15 healthcare institutions. Data from the general population were retrieved from the Kring community pharmacy Zuidlaren, also locatedin the northern part of the Netherlands.
Six different populations were investigated basedon the institution or ward wherethey were hospitalized:
1.patients from the general population identified by their prescription record as present in the drug dispensing database of a communitypharmacy without knowledge of theirdiagnosis; 2. patientshospitalized in a general hospital and admitted to internal medicine, neurology,pulmonary disease,and cardiology wards; 3. geriatric patients admitted to a nursing home with a somatic diagnosis; 4. psychogeriatric patients admittedto a generalpsychiatric hospital on wardsfor older patients with chronic mental disorders according to Diagnostic and Statistical Manual ofMental Disorders, 4threvision (DSM-1V)9; 5. psychiatric patients admittedto a general psychiatric hospital on wards for patients with chronic mental disorders according to DSM-IV; and 6. mentally retardedpatients admitted to long-termcare facilities for this population. To be included in the study,patients had to use at least one drug and be older than 18 years. Use of at least one drug was required because, in the general population, a SUbstantial number of people do not use any drug com-Pared with the number not using any drug in other populations. Inclusion of these people would have resulted in a deflated prevalence of patients using at least one drug metabolized by CYP2D6 in the general population compared with the other populations. In all populations, 150patients Were randomly selected. The study was performed in com-pliancewith the requirements of the human research committeeof the institutions regarding noninterventional studies with anonymizedpatient data. Prescription data for all patients were collected in June 2006.The prescription data present information on the current use of prescribed medicationsat the time of analysis.
OUTCOME MEASURES
The primary endpointwas the pointprevalence of use of at least one drug metabolized by CYP2D6.The secondary endpointwas the association betweenthe point prevalence of CYP2D6substrates and the age of the selectedpatients. From the information in the prescription file, a case record form was completed for each patient. Information gathered included institution, year of birth, sex, number of drugs, number of CYP2D6 substrates, and the name of the CYP2D6 substrates together with the first 3 characters of the Anatomical Therapeutic Chemical (ATC) classification (eg, N06Afor antidepressant drugs).
A drug was classified as a substrate of CYP2D6 when it was listed in the Flockhart CYP drug interaction table, published by the Indiana University Department of Medicine," This table is updatedfrequently (at least a few times a year), and drugs are includedif there is published evidence of metabolism, at least partly, by CYP2D6. To calculate the total proportion of CYP2D6 substrates, we includedall oral and parenteral drugs approved by the Dutch Medicines Evaluation Board or the European Medicines Evaluation Authority. Dermatologic preparations, stomatological preparations, oromucosal preparations, and indifferent (without pharmacologic active compound)oropharyngeal, nasal, and ocular preparations were excluded because of their limited systemic absorption. Depot injections and drugs prescribedto be used as needed were considered currently prescribed drugs.
DATA ANALYSIS
The prevalence of patients in different populations using at least one CYP2D6 substrate was compared with the prevalence of use in the general population (reference), using y} statistics. The risk of being treated with at least one drug metabolized by CYP2D6in a specific patientpopulation compared with that in the general population was expressedas a relative risk togetherwith 95% confidence interval.The association betweentreatment with at least one drug metabolized by CYP2D6and age was addressed similarly by comparing age groups, using patients younger than 30 years as the referencegroup. A p value of 0.05 or less was regarded as significant. Data were analyzed using SPSS 1l.0. In the geographical region of this study, we found prevalences of PMs and UMs of II % and 4%, respectively,"
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With the prevalence of patients in differentpopulations using at least one CYP2D6 substrate, it is possible to calculate a parameter in analogy to the parameter number needed to treat. We termed this parameternumber needed to genotype (NNG) to identify a patient withcompromised metabolism by CYP2D6 (PM or UM) who is treated with at leastone drug metabolized by CYP2D6.J2
In total, IS% of theselected patients (11 % PM + 4% UM) were expected to have compromised metabolism by CYP2D6. The NNG to find one patientwithcompromised metabolism by CYP2D6 was 6.7 (1/0.1S). Further,not all patients with compromised metabolism by CYP2D6 are treated with a drug metabolized by CYP2D6. Therefore, the NNG to find one patient with compromised metabolism by CYP2D6who is treated with at leastone drug metabolized by CYP2D6 was calculated by dividing 6.7 by the determined prevalence.
Results
In total, we analyzed the drug use profiles of 900 patientsdividedover 6 different patientpopulations. Geriatric patients used the largestnumberof drugs per patient (7.6), and patients from the generalpopulation used the smallest number of drugs per patient (3.0). Table 1 shows that patients from the general hospital (RR 1.81;9S% CI 1.26to 2.62), geriatric patients (RR 2.16; 9S% CI 1.26 to 2.62), psychogeriatric patients (RR 2.31; 9S% CI 1.63 to 3.27), and psychiatric patients (RR 2.44; 9S% CI 1.73 to 3.44) were treated more frequently with at leastone drug metabolized by CYP2D6compared with the general population.
Approximately SO% of psychiatric(S2%), psychogeriatric (49%), and geriatric(46%) patients used at least one drug metabolized by CYP2D6.The NNG to identify a patient with compromised metabolism by CYP2D6 who is treated with at least one drug metabolized by that isoenzyme is 13for these populations, given that approximately SO% of all patients are currently treated with at least one drug metabolized by CYP2D6 (1/(0.1S-o.50) = 13). Includingthe intermediate phenotype (patients with 1 mutant allele;prevalence approximately 33%13), the NNG is 4 for psychiatric, psychogeriatric, and geriatric patients(1/(O.1S + 0.33) • 0.50). Table 2 shows that the age of patients was not associated with the risk of being treated with at leastone drug metabolized by CYP2D6. Figure 1 provides an overview of the different CYP2D6 substrates (total numbers) prescribed in the different patient populations. In total, 416 different drugs metabolized by CYP2D6 were prescribed, of which 2S7(62%) wereclassified as antidepressants (ATC N06A) or antipsychotics (ATC NOSA), most frequently in psychiatric, psychogeriatric and geriatric patients.~-Bl ockers (ATC C07A) were the most frequently used drugs metabolized by CYP2D6 in geriatric patients and patients from the general population. The overall proportion of drugs metabolized by CYP2D6 in the6 different patient populations-general population (7.0%), general hospital 7.0%), geriatric (7.8%), mentally retarded (7.9%),psychogeriatric (8.6%),and psychiatric (11.8%)was not as high(20-30%)as suggested in the literature.v
Discussion
In this cross-sectional study, we found that the prevalence of patients treatedwith at leastone drug metabolized by CYP2D6 was high in psychiatric patients (S2%), psychogeriatric patients (49%), and geriatric patients (46%) compared with the prevalence in the general population (21 %). The prevalence of patients usingdrugs metabolized by CYP2D6was not associated with age.
Some issues must be addressed to interpret the results properly. First, we used the Flockharttable as a reference for determining whetherdrugs are a substrate of CYP2D6. We compared the table with 3 other references for CYP2D6substrates.P'" This comparison resultedin S discrepancies,with possible implications for the resultsin relationto the drugs mentioned in Figure 1 : metoclopramide, promethazine, mirtazapine, tolterodine, and zuclopenthixol. Zuclopenthixol, tolterodine, and mirtazapine are not present in the Flockhart table, despite the available evi- 
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objective. Second, it should be considered that we analyzed prescription data from patients in the same geographic region. The choice of drugs may be regionally determined; therefore, these data must be extrapolated to other regions carefully. However, the drugs were prescribed in different institutions by a substantial number of prescribers (>40) not participating in the same pharmacotherapy audit meetings. Therefore, we believe the results presented here will not be substantially different in other regions in at least the Netherlands, but probably also in other countries with comparable healthcare settings. Finally, we investigated several patient populations based on institution or ward. These criteria resulted in the inclusion of patients younger than 65 years in the geriatric (n = 23, with 8 pts. aged 60-65 y) and psychogeriatric (n =47, with 27 pts. aged 60-65 y) population. We chose these criteria because we wanted to analyze complete patient settings (general population, ward, institution) to identify target populations in which the introduction of CYP2D6 genotyping is most likely to be cost-effective. Analysis of psychogeriatric and geriatric patients without patients younger than 65 years showed results similar to those presented here.
Knowledge about the proportion of drugs metabolized by CYP2D6 is important for implementation of CYP2D6 genotyping in clinical practice. It is suggested that 20-30% of all drugs are metabolized by CYP2D6. 4 ,5 We found a lower proportion of the use of drugs metabolized by CYP2D6 in all patient populations, with the lowest proportion (7.0%) in the general hospital and the general population and the highest proportion (11.8%) in psychiatric patients. However, looking at the prevalence of patients treated with at least one drug metabolized by CYP2D6, we found a high prevalence in several populations, specifically, psychiatric, psychogeriatric, and geriatric patients who were at risk for treatment with at least one drug metabolized by CYP2D6 with a prevalence of approximately 50%. The NNG to find one patient with compromised metabolism by CYP2D6 who uses a drug metabolized by that isoenzyme at a specific moment was only 13. The NNG would probably be much lower if we could establish the lifetime risk, or even the one year risk, for treatment with a drug metabolized by CYP2D6. We expected that mentally retarded patients and older patients would be treated frequently with drugs metabolized by CYP2D6 as well, but we could not support this hypothesis with our data. Apparently, specific patient populations admitted to particular institutions or wards are at risk for treatment with drugs metabolized by CYP2D6. Our study was not intended to provide evidence regarding the clinical relevance of CYP2D6 genotyping; it merely shows that if genotyping is relevant for patient care, the highest probability of cost-effectiveness will most likely be in these specific patient populations (ie, psychiatric, psychogeriatric, geriatric).
Drugs metabolized by CYP2D6 and prescribed in different populations were most frequently (62%) antidepressants (ATC N06A) and antipsychotics (ATC N05A). Some recently introduced psychotropic drugs are not primarily metabolized by CYP2D6 (eg, citalopram, sertraline, olanzapine, quetiapine). However, these data show that, despite the introduction of these drugs, CYP2D6 remains an important metabolizing enzyme in daily clinical practice. Additionally, it has been suggested that pharmaceutical industries are reluctant about the introduction of primary substrates for CYP2D6 because of proposed problems with drug interactions and the polymorphic metabolism.v" Many companies will not continue to develop drug candidates metabolized by CYP2D6 unless they offer unique properties. This can result not only in decreased influence of CYP2D6 in the metabolism of drugs in the near future, but also the possible denial of potential effective drugs to patients." However, although we do not know how many CYP2D6 substrates were withdrawn by pharmaceutical industries before they reached the market in 2005 and 2006, several psychotropic agents that are substrates for CYP2D6 (aripiprazole, duloxetine, atomoxetine) were introduced, suggesting that it will remain an important metabolizing enzyme for the near future.25-%7
Conclusions
In our study, several populations had a high prevalence of patients who were treated with at least one drug metabolized by CYP2D6, with most of those drugs being antidepressants or antipsychotics. These findings suggest that populations treated with these drugs may benefit most from implementation of CYP2D6 genotyping.
EXTRAcrõ
ODUCCI6N:
A pesar del gran nnmerode estudiosque han IOvestigado la relevanciac1fnica potencial del genotipado CYP2D6 en la prevenci6n del ftacaso terapeutico (ej,eficaciainsuficiente y/0 efectos adversos inaceptables), la prevalencia de pacientes que utilizan f4rmacos metabolizados por el CYP2D6es relativamente desconocida. 0BJEnvo: Investigarla prevalencia de pacientesque utilizanflirmacos metabolizados por el CYP2D6en diferentes poblaciones de pacientes.
MEtoDOS: En este estudiocruzadose investigaron 6 poblaciones de pacientes diferentes: poblaci6ngeneral,poblaci6ngeneralhospitalizada, POblaci6n geriatrica, psicogeriatrica, psiquiatrica y enferrnos con retraso mental.Decada poblaci6n,se seleccionaron aleatoriamente 150 pacientes adultosque utilizabanal menosun medicarnento. Los resUltados principales fueron la prevalencia de pacientesque utilizaban al menosun farrnaco metabolizado por el CYP2D6.La prevalencia de pacientes que utilizaban al menosun sustratoCYP2D6en diferentes POblaciones fue comparadacon la poblaci6ngeneralutilizando la PTUeba estadfstica del ' 1,1. Los datos se expresaron como el riesgo relativo(RR) con un 95% de intervalo de confianza(95% IC).
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RE.~ULTADOS:
Los pacientes procedentes de hospitalizaci6n (RR 1.81; 95% IC 1.26y 2.62),los pacientes geriatricos (RR 2.16;95% IC 1.26Y2.62), lospacientes psicogeriatricos (RR2.31;95% IC 1.63Y3.27),y los pacientes psiquiatricos (RR 2.44;95% IC 1.73 Y3.44)fueron tratados mas frecuentemente con al menosun farmaco con metabolizaci6n por el CYP206 comparado con los pacientes en la poblaci6n general. Aproximadamente el 50%de lospacientes psiquiatricos (52%), psicogeriatricos (49%),Ygeriatricos (46%)utilizaban al menosun farrnaco metabolizado porel CYP2D6.En total,416 farmacos metabolizados porel CYP2D6fueron prescritos, siendo257 (62%)de los farmacos clasificados comoantidepresivos (ATC N06A)0 antipsic6ticos (ATC N05A). CONCLUSIONES: Diversaspoblaciones de pacientes (psiquiatricos, psicogeriatricos, geriatricos) presentanuna alta prevalencia de tratamientos con al menos un medicamento metabolizado por el CYP2D6.Los farmacosmetabolizados por el CYP2D6 fueron fundamentalmente antidepresivos 0 antipsic6ticos (62%). Este estudio no proporeiona evidenciasobre la relevancia c1inica del genotipado CYP2D6,pero simplemente muestraque, si el genotipadoCYP2D6 se considerarelevantepara el tratamiento de los pacientes,el mayor ratio de coste-efectividad se obtendramuy probablemente en poblaciones de pacientes especfficas. 
